The Lewy Body Dementia Association (LBDA), the leading advocacy group dedicated to raising awareness and advancing research about Lewy body dementia (LBD), announced today the launch of the LBDA Research Centers of Excellence (RCOE). This collaboration features 24 preeminent academic medical research centers across the United States, coordinated by Mayo Clinic.
The LBDA RCOE program will provide a centralized, coordinated research resource, supporting an expanded effort in conducting clinical trials related to LBD while helping to provide expert clinical care for patients, families and caregivers.
“Successful clinical trials are the holy grail for all the stakeholders in the Lewy body dementia treatment community, so the goal of the Research Centers of Excellence program is to benefit patients with the disease,” said Dr. Bradley Boeve, Mayo Clinic’s LBDA RCOE lead primary investigator. “Lewy body dementia is chronically underdiagnosed, so we seek to address a decades-old challenge of finding and enrolling enough correctly diagnosed patients, working with clinicians and staff who understand the disease, and reaching the right patients and families to encourage participation in clinical trials. Now we can address all three. The centers involved in the program are working together with a common goal to improve the understanding of the disease in the scientific, medical and general public communities.”
LBDA’s RCOE program aims to establish a clinical trials-ready network of leading institutions that share the common vision of providing the highest level of clinical care over the course of LBD treatment.
In addition, the RCOE network seeks to increase access to support for caregivers and people living with LBD, increase the knowledge of LBD among the medical community, and construct administrative infrastructure and generate the resources necessary to further advance LBD research and care.